SEC Tracker
Get the app

Fate Therapeutics FATE

Fate entered into a sales agreement with Leerink Partners

Securities offering

Form
424B5
Filed
Importance
Routine
  1. Up to $100,000,000 in common stock sales
  2. Sales through Leerink Partners as sales agent
  3. Commission rate up to 3.0% of gross proceeds

Written from the 424B5 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Fate Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Protalix BioTherapeutics PLX public float $113M, Jun 30, 2025
  2. Caribou Biosciences CRBU public float $113M, Jun 30, 2025
  3. Protara Therapeutics PRTO public float $112M, Jun 30, 2025
  4. TuHURA Biosciences HURA public float $111M, Jun 30, 2025
  5. Alector ALEC public float $115M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.